These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
352 related articles for article (PubMed ID: 32900676)
1. Assessing the Impact of the Absence of Detrusor Muscle in Ta Low-grade Urothelial Carcinoma of the Bladder on Recurrence-free Survival. Mastroianni R; Brassetti A; Krajewski W; Zdrojowy R; Salhi YA; Anceschi U; Bove AM; Carbone A; De Nunzio C; Fuschi A; Ferriero M; Nacchia A; Pastore AL; Tema G; Tuderti G; Gallucci M; Simone G Eur Urol Focus; 2021 Nov; 7(6):1324-1331. PubMed ID: 32900676 [TBL] [Abstract][Full Text] [Related]
2. Implications of Guideline-based, Risk-stratified Restaging Transurethral Resection of High-grade Ta Urothelial Carcinoma on Bacillus Calmette-Guérin Therapy Outcomes. Hensley PJ; Bree KK; Brooks N; Matulay J; Li R; Nogueras-Gonzalez GM; Nagaraju S; Navai N; Grossman HB; Dinney CP; Kamat AM Eur Urol Oncol; 2022 Jun; 5(3):347-356. PubMed ID: 33935020 [TBL] [Abstract][Full Text] [Related]
3. Good quality white-light transurethral resection of bladder tumours (GQ-WLTURBT) with experienced surgeons performing complete resections and obtaining detrusor muscle reduces early recurrence in new non-muscle-invasive bladder cancer: validation across time and place and recommendation for benchmarking. Mariappan P; Finney SM; Head E; Somani BK; Zachou A; Smith G; Mishriki SF; N'Dow J; Grigor KM; BJU Int; 2012 Jun; 109(11):1666-73. PubMed ID: 22044434 [TBL] [Abstract][Full Text] [Related]
4. Papillary urothelial neoplasm of low malignant potential (PUN-LMP): Still a meaningful histo-pathological grade category for Ta, noninvasive bladder tumors in 2019? Hentschel AE; van Rhijn BWG; Bründl J; Compérat EM; Plass K; Rodríguez O; Henríquez JDS; Hernández V; de la Peña E; Alemany I; Turturica D; Pisano F; Soria F; Čapoun O; Bauerová L; Pešl M; Bruins HM; Runneboom W; Herdegen S; Breyer J; Brisuda A; Scavarda-Lamberti A; Calatrava A; Rubio-Briones J; Seles M; Mannweiler S; Bosschieter J; Kusuma VRM; Ashabere D; Huebner N; Cotte J; Mertens LS; Cohen D; Lunelli L; Cussenot O; Sheikh SE; Volanis D; Coté JF; Rouprêt M; Haitel A; Shariat SF; Mostafid AH; Nieuwenhuijzen JA; Zigeuner R; Dominguez-Escrig JL; Hacek J; Zlotta AR; Burger M; Evert M; Hulsbergen-van de Kaa CA; van der Heijden AG; Kiemeney LALM; Soukup V; Molinaro L; Gontero P; Llorente C; Algaba F; Palou J; N'Dow J; Babjuk M; van der Kwast TH; Sylvester RJ Urol Oncol; 2020 May; 38(5):440-448. PubMed ID: 31704141 [TBL] [Abstract][Full Text] [Related]
5. Impact of substratification on predicting oncological outcomes in patients with primary high-risk non-muscle-invasive bladder cancer who underwent transurethral resection of bladder tumor. Fujita N; Hatakeyama S; Momota M; Tobisawa Y; Yoneyama T; Yamamoto H; Imai A; Ito H; Yoneyama T; Hashimoto Y; Yoshikawa K; Ohyama C Urol Oncol; 2020 Oct; 38(10):795.e9-795.e17. PubMed ID: 32417111 [TBL] [Abstract][Full Text] [Related]
6. Comparison of Detrusor Muscle Sampling Rate in Monopolar and Bipolar Transurethral Resection of Bladder Tumor: A Randomized Trial. Teoh JY; Chan ES; Yip SY; Tam HM; Chiu PK; Yee CH; Wong HM; Chan CK; Hou SS; Ng CF Ann Surg Oncol; 2017 May; 24(5):1428-1434. PubMed ID: 27882470 [TBL] [Abstract][Full Text] [Related]
7. Combination of hyperthermia and intravesical chemotherapy for the treatment of pT1 stage bladder cancer: A retrospectively clinical study. Wang S; Yu Z; Du P; Cao Y; Yang X; Ma J; Tang X; Zhang Q; Yang Y Asia Pac J Clin Oncol; 2024 Apr; 20(2):228-233. PubMed ID: 36656047 [TBL] [Abstract][Full Text] [Related]
8. Time between first and second transurethral resection of bladder tumors in patients with high-grade T1 tumors: is it a risk factor for residual tumor detection? Süer E; Özcan C; Baltacı S; Gülpınar Ö; Burgu B; Haliloğlu A; Bedük Y Urol Int; 2013; 91(2):182-6. PubMed ID: 23751593 [TBL] [Abstract][Full Text] [Related]
9. Detrusor Muscle in TUR-Derived Bladder Tumor Specimens: Can We Actually Improve the Surgical Quality? Capogrosso P; Capitanio U; Ventimiglia E; Boeri L; Briganti A; Colombo R; Montorsi F; Salonia A J Endourol; 2016 Apr; 30(4):400-5. PubMed ID: 26597334 [TBL] [Abstract][Full Text] [Related]
10. Comparative assessment of disease recurrence after transurethral resection of non-muscle-invasive bladder cancer with and without a photodynamic diagnosis using 5-aminolevulinic acid: a propensity score-matching analysis. Matsushita Y; Miyake M; Nishimura N; Nishimoto K; Fukuhara H; Kobayashi K; Oyama M; Inoue K; Matsuyama H; Fujimoto K; Miyake H Int J Clin Oncol; 2024 Feb; 29(2):205-212. PubMed ID: 38112832 [TBL] [Abstract][Full Text] [Related]
11. Cell-cycle markers do not improve discrimination of EORTC and CUETO risk models in predicting recurrence and progression of non-muscle-invasive high-grade bladder cancer. Passoni N; Gayed B; Kapur P; Sagalowsky AI; Shariat SF; Lotan Y Urol Oncol; 2016 Nov; 34(11):485.e7-485.e14. PubMed ID: 27637323 [TBL] [Abstract][Full Text] [Related]
12. Quality Control Indicators for Transurethral Resection of Bladder Tumor: Results from an Embedded Belgian Multicenter Prospective Registry. Muilwijk T; Akand M; Raskin Y; Jorissen C; Vander Eeckt K; Van Bruwaene S; Van Cleynenbreugel B; Joniau S; Van Der Aa F Eur Urol Oncol; 2023 Aug; 6(4):422-430. PubMed ID: 36543720 [TBL] [Abstract][Full Text] [Related]
13. Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign. Li R; Metcalfe MJ; Tabayoyong WB; Guo CC; Nogueras González GM; Navai N; Grossman HB; Dinney CP; Kamat AM Eur Urol Oncol; 2019 May; 2(3):286-293. PubMed ID: 31200843 [TBL] [Abstract][Full Text] [Related]
14. The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911. Oddens JR; Sylvester RJ; Brausi MA; Kirkels WJ; van de Beek C; van Andel G; de Reijke TM; Prescott S; Witjes JA; Oosterlinck W Eur Urol; 2014 Oct; 66(4):694-701. PubMed ID: 24948466 [TBL] [Abstract][Full Text] [Related]
15. Correlation between urine cytology results on the day after overnight continuous saline irrigation following transurethral resection of bladder tumor and bladder tumor recurrence. Kim DH; Choi MS; Choi JH; Lee C; Jeh SU; Kam SC; Hwa JS; Hyun JS; Choi SM Investig Clin Urol; 2024 May; 65(3):279-285. PubMed ID: 38714518 [TBL] [Abstract][Full Text] [Related]
16. Presence of detrusor muscle in bladder tumor specimens--predictors and effect on outcome as a measure of resection quality. Shoshany O; Mano R; Margel D; Baniel J; Yossepowitch O Urol Oncol; 2014 Jan; 32(1):40.e17-22. PubMed ID: 23911682 [TBL] [Abstract][Full Text] [Related]
17. The Impact of Restaging Transurethral Resection of Bladder Tumor on Survival Parameters in T1 Nonmuscle-Invasive Bladder Cancer: Systematic Review and Meta-Analysis. Krajewski W; Nowak Ł; Poletajew S; Tukiendorf A; Moschini M; Mari A; Di Trapani E; Xylinas E; Kiełb P; Wełna M; Zdrojowy R J Endourol; 2020 Aug; 34(8):795-804. PubMed ID: 32336149 [No Abstract] [Full Text] [Related]
18. Stratifying risk for multiple, recurrent, and large (≥3 cm) Ta, G1/G2 tumors in non-muscle-invasive bladder cancer. Suh J; Jung JH; Kwak C; Kim HH; Ku JH Investig Clin Urol; 2021 Jul; 62(4):408-415. PubMed ID: 34190435 [TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of non-muscle-invasive bladder tumor history in patients with upper urinary tract urothelial carcinoma. Milojevic B; Djokic M; Sipetic-Grujicic S; Grozdic Milojevic I; Vuksanovic A; Nikic P; Vukovic I; Djordjevic D; Bumbasirevic U; Tulic C Urol Oncol; 2013 Nov; 31(8):1615-20. PubMed ID: 22521771 [TBL] [Abstract][Full Text] [Related]
20. Pathology in repeated transurethral resection of a bladder tumor as a risk factor for prognosis of high-risk non-muscle-invasive bladder cancer. Tae BS; Jeong CW; Kwak C; Kim HH; Moon KC; Ku JH PLoS One; 2017; 12(12):e0189354. PubMed ID: 29244843 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]